United Therapeutics (NASDAQ:UTHR) Price Target Lowered to $613.00 at Bank of America

United Therapeutics (NASDAQ:UTHR) had its price target lowered by Bank of America from $620.00 to $613.00 in a report published on Friday,Benzinga reports. The firm currently has a neutral rating on the biotechnology company’s stock.

Several other equities analysts also recently issued reports on the stock. Cantor Fitzgerald upped their price objective on shares of United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research note on Thursday, March 12th. Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a report on Thursday, June 11th. Royal Bank Of Canada upped their target price on United Therapeutics from $701.00 to $704.00 and gave the company an “outperform” rating in a research report on Tuesday. HC Wainwright raised their price target on United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a research note on Tuesday, March 31st. Finally, Morgan Stanley set a $516.00 price target on United Therapeutics in a research report on Thursday, May 7th. Ten research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $644.82.

United Therapeutics Trading Down 1.0%

Shares of NASDAQ:UTHR opened at $547.06 on Friday. The company has a market capitalization of $23.22 billion, a PE ratio of 20.19, a P/E/G ratio of 1.81 and a beta of 0.58. United Therapeutics has a twelve month low of $272.12 and a twelve month high of $609.35. The firm has a 50 day simple moving average of $556.70 and a 200-day simple moving average of $529.44.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The company had revenue of $781.50 million during the quarter, compared to analysts’ expectations of $797.40 million. During the same period last year, the business earned $6.63 earnings per share. The company’s quarterly revenue was down 1.6% on a year-over-year basis. As a group, equities research analysts predict that United Therapeutics will post 26.63 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CFO James Edgemond sold 10,000 shares of the firm’s stock in a transaction on Monday, April 13th. The shares were sold at an average price of $574.88, for a total value of $5,748,800.00. Following the completion of the sale, the chief financial officer owned 18,876 shares in the company, valued at approximately $10,851,434.88. This trade represents a 34.63% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last ninety days, insiders have sold 603,543 shares of company stock worth $339,592,598. 8.60% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Torren Management LLC acquired a new stake in United Therapeutics in the fourth quarter valued at about $26,000. Activest Wealth Management increased its position in United Therapeutics by 1,400.0% during the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 56 shares during the period. WealthCollab LLC increased its position in United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 38 shares during the period. Rakuten Securities Inc. raised its stake in shares of United Therapeutics by 76.7% during the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 46 shares in the last quarter. Finally, Entrust Financial LLC purchased a new position in shares of United Therapeutics during the 4th quarter worth approximately $31,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.